{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:31:51Z","timestamp":1793734311117,"version":"4.6.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015990","name":"Sanofi K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015990","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016240","name":"Nihon Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016240","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016242","name":"Boston Scientific Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016242","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016259","name":"Mylan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015731","name":"Bayer Yakuhin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004169","name":"Meiji Seika Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004169","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015377","name":"Nihon Medi-Physics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015377","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016288","name":"Kissei","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016288","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017346","name":"Boehringer Ingelheim Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017346","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.parkreldis.2020.04.012","type":"journal-article","created":{"date-parts":[[2020,5,3]],"date-time":"2020-05-03T21:28:43Z","timestamp":1588541323000},"page":"17-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"special_numbering":"C","title":["Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II\/III study"],"prefix":"10.1016","volume":"75","author":[{"given":"Nobutaka","family":"Hattori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Sasagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Nomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2020.04.012_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1468-1331.2012.03866.x","article-title":"Summary of the recommendations of the EFNS\/MDS-ES review on therapeutic management of Parkinson's disease","volume":"20","author":"Ferreira","year":"2013","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.parkreldis.2020.04.012_bib2","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00702-018-1900-6","article-title":"Levodopa-induced dyskinesia: clinical features, incidence, and risk factors","volume":"125","author":"Tran","year":"2018","journal-title":"J. Neural. Transm. (Vienna)"},{"key":"10.1016\/j.parkreldis.2020.04.012_bib3","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.2169\/internalmedicine.56.7667","article-title":"The risk factors for the wearing-off phenomenon in Parkinson's disease in Japan: a cross-sectional, multicenter study","volume":"56","author":"Ouma","year":"2017","journal-title":"Intern. Med."},{"key":"10.1016\/j.parkreldis.2020.04.012_bib4","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s40265-013-0105-4","article-title":"Non-dopaminergic treatments for motor control in Parkinson's disease","volume":"73","author":"Fox","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.parkreldis.2020.04.012_bib5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jns.2012.08.030","article-title":"Istradefylline, an adenosine A2A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis","volume":"324","author":"Chen","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2020.04.012_bib6","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00702-018-1869-1","article-title":"Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia","volume":"125","author":"Perez-Lloret","year":"2018","journal-title":"J. Neural. Transm. (Vienna)"},{"key":"10.1016\/j.parkreldis.2020.04.012_bib7","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/jnr.23577","article-title":"1-[2-(4-Benzyloxyphenoxy)Ethyl]Imidazole inhibits monoamine oxidase B and protects against neuronal loss and behavioral impairment in rodent models of Parkinson's disease","volume":"93","author":"Chung","year":"2015","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.parkreldis.2020.04.012_bib8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1124\/jpet.117.245100","article-title":"Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia","volume":"364","author":"Morari","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.parkreldis.2020.04.012_bib9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mds.25751","article-title":"Study 016 Investigators, Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations","volume":"29","author":"Borgohain","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.04.012_bib10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jamaneurol.2016.4467","article-title":"Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a randomized clinical trial","volume":"74","author":"Schapira","year":"2017","journal-title":"JAMA. Neurol."},{"key":"10.1016\/j.parkreldis.2020.04.012_bib11","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/mds.25961","article-title":"Study 018 Investigators, Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease","volume":"29","author":"Borgohain","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.04.012_bib12","first-page":"475","article-title":"Long-term effects of safinamide on dyskinesia in mid- to late-stage Parkinson's Disease: a post-hoc analysis","volume":"5","author":"Cattaneo","year":"2015","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.parkreldis.2020.04.012_bib13","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/mds.23517","article-title":"Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease","volume":"26","author":"Stowe","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.04.012_bib14","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","article-title":"For the LARGO study group, Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given once daily, study): a randomised, double-blind, parallel-group trial","volume":"365","author":"Rascol","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2020.04.012_bib15","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1212\/01.wnl.0000210692.95595.1c","article-title":"Parkinson Study Group TEMPO and PRESTO Investigators, Safety of rasagiline in elderly patients with Parkinson disease","volume":"66","author":"Goetz","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.04.012_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.parkreldis.2018.04.025","article-title":"Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off: a phase 2\/3, randomized, double-blind, placebo-controlled, multicenter study","volume":"53","author":"Hattori","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2020.04.012_bib17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1212\/01.wnl.0000250236.75053.16","article-title":"Japan Zonisamide on PD Study Group, Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study","volume":"68","author":"Murata","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.04.012_bib18","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2174\/187152709789824606","article-title":"Glutamate receptors as therapeutic targets for Parkinson's disease","volume":"8","author":"Johnson","year":"2009","journal-title":"CNS Neurol. Disord. - Drug Targets"},{"key":"10.1016\/j.parkreldis.2020.04.012_bib19","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1002\/mds.5557","article-title":"Amantadine and other antiglutamate agents: management of Parkinson's disease","volume":"17","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.04.012_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178896","article-title":"Determinants of generic and specific health-related quality of life in patients with Parkinson's disease","volume":"12","author":"Tu","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.parkreldis.2020.04.012_bib21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.parkreldis.2013.10.005","article-title":"The impact of non-motor symptoms on the Health-Related Quality of Life of Parkinson's disease patients from Southwest China","volume":"20","author":"Song","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2020.04.012_bib22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.phrs.2003.12.004","article-title":"Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity","volume":"50","author":"Marzo","year":"2004","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.parkreldis.2020.04.012_bib23","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/mds.23517","article-title":"Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease","volume":"26","author":"Stowe","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.04.012_bib24","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.parkreldis.2013.01.009","article-title":"Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys","volume":"19","author":"Gr\u00e9goire","year":"2013","journal-title":"Park. Relat. Disord."}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802020301073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802020301073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T19:13:34Z","timestamp":1762370014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802020301073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":24,"alternative-id":["S1353802020301073"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2020.04.012","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II\/III study","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2020.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}